3 results
Approved WMOCompleted
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
Approved WMOPending
Primary Objective: The primary objective is to investigate whether EUS-TCB had an added value on EUS-FNA alone. Secondary Objective(s): The secondary objective is to study whether EUS-TCB does not have a higher complication rate than EUS-FNA alone.
Approved WMOCompleted
Main objective is to compare detection efficacy of 18F-PSMA-1007 PET-CT to 18F-Fluciclovine, in patients with early biochemical recurrence of prostate cancer.